Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Costantino

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Future Medicinal Chemistry|March 25, 2011
Drug delivery to the CNS and polymeric nanoparticulate carriersLuca Costantino
Expert Opinion on Therapeutic Patents|July 20, 2012
Novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors (WO2012035124): a patent evaluationLuca Costantino
Expert Opinion on Therapeutic Patents|April 28, 2012
Growth hormone secretagogue receptor antagonistsLuca Costantino
Expert Opinion on Therapeutic Patents|October 14, 2010
Methods for synthesis and uses of inhibitors of ghrelin O-acyltransferase inhibitors as potential therapeutic agents for obesity and diabetesLuca Costantino
Future Medicinal Chemistry|March 24, 2011
Ghrelin receptor modulators and their therapeutic potentialLuca Costantino, Daniela Barlocco
Current Medicinal Chemistry|February 7, 2006
Privileged structures as leads in medicinal chemistryLuca Costantino, Daniela Barlocco
Journal of Medicinal Chemistry|March 24, 2016
Ten Years of Medicinal Chemistry (2005-2014) in the Journal of Medicinal Chemistry: Country of Contributors, Topics, and Public-Private PartnershipsLuca Costantino, Daniela Barlocco
Expert Opinion on Therapeutic Patents|July 23, 2014
Ghrelin receptor modulators: a patent review (2011 - 2014)Luca Costantino, Daniela Barlocco
Future Medicinal Chemistry|December 22, 2012
Challenges in the design of multitarget drugs against multifactorial pathologies: a new life for medicinal chemistry?Luca Costantino, Daniela Barlocco
Current Medicinal Chemistry|May 14, 2008
STAT 3 as a target for cancer drug discoveryLuca Costantino, Daniela Barlocco
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Future Medicinal Chemistry|March 25, 2011
Drug delivery to the CNS and polymeric nanoparticulate carriersLuca Costantino
Expert Opinion on Therapeutic Patents|July 20, 2012
Novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors (WO2012035124): a patent evaluationLuca Costantino
Expert Opinion on Therapeutic Patents|April 28, 2012
Growth hormone secretagogue receptor antagonistsLuca Costantino
Expert Opinion on Therapeutic Patents|October 14, 2010
Methods for synthesis and uses of inhibitors of ghrelin O-acyltransferase inhibitors as potential therapeutic agents for obesity and diabetesLuca Costantino
Future Medicinal Chemistry|March 24, 2011
Ghrelin receptor modulators and their therapeutic potentialLuca Costantino, Daniela Barlocco
Current Medicinal Chemistry|February 7, 2006
Privileged structures as leads in medicinal chemistryLuca Costantino, Daniela Barlocco
Journal of Medicinal Chemistry|March 24, 2016
Ten Years of Medicinal Chemistry (2005-2014) in the Journal of Medicinal Chemistry: Country of Contributors, Topics, and Public-Private PartnershipsLuca Costantino, Daniela Barlocco
Expert Opinion on Therapeutic Patents|July 23, 2014
Ghrelin receptor modulators: a patent review (2011 - 2014)Luca Costantino, Daniela Barlocco
Future Medicinal Chemistry|December 22, 2012
Challenges in the design of multitarget drugs against multifactorial pathologies: a new life for medicinal chemistry?Luca Costantino, Daniela Barlocco
Current Medicinal Chemistry|May 14, 2008
STAT 3 as a target for cancer drug discoveryLuca Costantino, Daniela Barlocco
Pageof 6